Case Reports in Clinical Medicine

Volume 12, Issue 10 (October 2023)

ISSN Print: 2325-7075   ISSN Online: 2325-7083

Google-based Impact Factor: 0.2  Citations  

Magnusiomyces capitatus in Immune-Competent Patients with Pulmonary Haemorrhage and Systemic Lupus Erythematosus

HTML  XML Download Download as PDF (Size: 835KB)  PP. 408-417  
DOI: 10.4236/crcm.2023.1210055    60 Downloads   243 Views  

ABSTRACT

Invasive fungal infections have grown significantly over the last two decades, owing to an increase in immunocompromised hosts and geriatric patients. When the host’s defenses are compromised, such infections are associated with severe morbidity and mortality. Here, a rare case of fungal infection in a 61-year-old immunocompetent male patient from Saudi Arabia was reported, who suffered from pulmonary hemorrhage and Systemic Lupus Erythematous. Bronchoalveolar Lavage was used as a diagnostic tool to identify the fungus reported in the case. The pathogenic fungal specie identified as Magnusiomyces capitatus, in macroscopic and microscopic morphological characteristics of the colonies. Based on clinical evidence, liposomal amphotericin formulation was recommended for initial therapy against fungal infection. Also, liposomal amphotericin B induced mycological eradication up to 70 percent in patients with proven Magnusiomyces capitatus infection. In addition to addressing suspected Systemic lupus erythematosus, the patient’s health has improved with no evidence of pulmonary bleeding and hemoptysis.

Share and Cite:

Ahmed, W. , Almakki, A. , Bashinim, A. , Mohamed, A. , Kalkami, A. and AbuRageila, M. (2023) Magnusiomyces capitatus in Immune-Competent Patients with Pulmonary Haemorrhage and Systemic Lupus Erythematosus. Case Reports in Clinical Medicine, 12, 408-417. doi: 10.4236/crcm.2023.1210055.

Cited by

No relevant information.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.